New Date for Anticipated VentriPoint Diagnostic System Launch, Alpha
Testing Commencement Highlight Management Discussion and Analysis
SEATTLE, Aug. 29 /PRNewswire-FirstCall/ -- VentriPoint Diagnostics (TSX: VPT) today announced that it has filed its management discussion and analysis (MD&A), as well as its unaudited financial results for the three months ended June 30, 2008, with the Canadian Securities Administrators through the SEDAR filing system.
In its MD&A, VentriPoint describes that because of the recent accomplishments by its development team, the commercial product release of the VentriPoint Diagnostic System is now anticipated to commence in January 2009 instead of March 2009 as previously expected. Other recent milestones include the approval and commencement of alpha testing, transition of the Knowledge Reconstruction Database to its commercial and secure off-site facility, and initiation of the design and production of the product training guide and user's manual.
"Our team has been working diligently to bring the VentriPoint Diagnostic System to market to offer accurate heart measurements in a rapid and inexpensive manner that is not currently available," said Joseph Ashley, CEO of VentriPoint Diagnostics. "We have commenced in-house alpha testing, and we look forward to shipping our units for beta testing in October."
In its unaudited financial results, VentriPoint reported a consolidated net loss of $1,062,182 for the three months ended June 30, 2008, or $0.03 per share, compared to a net loss of $193,038, or $0.02 per share for the three months ended June 30, 2007. The increase in net loss is attributed to planned expenditures to accelerate the development of the VentriPoint Diagnostic System.
For the three months ended June 30, 2008, research and development expenses totaled $651,276, compared to $143,563 for the three months ended June 30, 2007. The largest research and development expense for the three months ended June 30, 2008 was payroll costs to build a highly qualified research and development team.
VentriPoint reported a foreign exchange loss of $99,568 as the result of a change in the currency exchange rate used to translate Canadian monetary items into the US dollar on the date of translation of June 30, 2008.
About VentriPoint Diagnostics
VentriPoint creates diagnostic tools to monitor patients with heart
disease -- the number one cause of death in developed countries. By using
images produced from existing medical imaging systems, the VentriPoint
Diagnostic System generates accurate heart measurements in a rapid and
inexpensive manner not currently available. This breakthrough diagnostic
tool is based upon patented technology received by VentriPoint through its
exclusive technology license with the University of Washington. The
VentriPoint Diagnostic System, together with its associated online service,
is being developed for a variety of heart related disease states, including
congenital heart disease.
For further information, please contact:
Edward Garth, Chief Financial Officer
VentriPoint Diagnostics Ltd.
Telephone: (206) 283-0221, ext. 402
Facsimile: (206) 283-2309
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
VentriPoint Media Contact:
Russo Partners LLC
|SOURCE VentriPoint Diagnostics|
Copyright©2008 PR Newswire.
All rights reserved